{"id":"W4412724750","doi":"10.1080/14796694.2025.2535280","title":"SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary","funders":"Seagen; Pfizer","keywords":"Pembrolizumab; Medicine; Oncology; Internal medicine; Antibody-drug conjugate; Chemotherapy; Metastatic Urothelial Carcinoma; Antibody; Immunotherapy; Cancer; Urothelial carcinoma; Monoclonal antibody; Immunology; Bladder cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001062831,0.0003125811,0.0007475092,0.0002204464,0.0000917405,0.00001870877,0.0001505763,0.000172876,0.000442405],"category_scores_gemma":[0.00004085754,0.0002068335,0.00007618467,0.0004368135,0.0001272558,0.00009024121,0.00005415414,0.0004042674,0.00003248393],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005394647,"about_ca_system_score_gemma":0.001814924,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000280611,"about_ca_topic_score_gemma":0.001796827,"domain_scores_codex":[0.9982622,0.0001577722,0.00037316,0.0005020952,0.0002184307,0.0004863697],"domain_scores_gemma":[0.9991866,0.0001036352,0.0001017413,0.0003745392,0.00009502425,0.0001384154],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.1526619,0.008232995,0.1066462,0.001814791,0.001646347,0.01501129,0.00499958,0.0002586305,0.01267591,0.00309272,0.01249329,0.6804664],"study_design_scores_gemma":[0.1793668,0.02078207,0.3336727,0.001652816,0.002067776,0.001571692,0.005134701,0.000379234,0.006425821,0.0006753834,0.4471184,0.001152582],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9257101,0.0028907,0.0008506494,0.009862917,0.001449429,0.00244502,0.00006831944,0.0001721851,0.05655069],"genre_scores_gemma":[0.9875935,0.00007661296,0.00443516,0.002497759,0.0004026291,0.000252437,0.00004963448,0.00004605099,0.0046462],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6793138,"threshold_uncertainty_score":0.8434424,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0126343344582403,"score_gpt":0.3140959120053023,"score_spread":0.301461577547062,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}